540 related articles for article (PubMed ID: 18922928)
1. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
Chin LJ; Ratner E; Leng S; Zhai R; Nallur S; Babar I; Muller RU; Straka E; Su L; Burki EA; Crowell RE; Patel R; Kulkarni T; Homer R; Zelterman D; Kidd KK; Zhu Y; Christiani DC; Belinsky SA; Slack FJ; Weidhaas JB
Cancer Res; 2008 Oct; 68(20):8535-40. PubMed ID: 18922928
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.
Nelson HH; Christensen BC; Plaza SL; Wiencke JK; Marsit CJ; Kelsey KT
Lung Cancer; 2010 Jul; 69(1):51-3. PubMed ID: 19854534
[TBL] [Abstract][Full Text] [Related]
3. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.
Kim M; Chen X; Chin LJ; Paranjape T; Speed WC; Kidd KK; Zhao H; Weidhaas JB; Slack FJ
Cell Cycle; 2014; 13(6):1030-40. PubMed ID: 24552817
[TBL] [Abstract][Full Text] [Related]
4. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
[TBL] [Abstract][Full Text] [Related]
5. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
[TBL] [Abstract][Full Text] [Related]
6. A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD.
Hu H; Zhang L; Teng G; Wu Y; Chen Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():1641-9. PubMed ID: 26316738
[TBL] [Abstract][Full Text] [Related]
7. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A
Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149
[TBL] [Abstract][Full Text] [Related]
8. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
[TBL] [Abstract][Full Text] [Related]
9. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Ganzinelli M; Rulli E; Caiola E; Garassino MC; Broggini M; Copreni E; Piva S; Longo F; Labianca R; Bareggi C; Fabbri MA; Martelli O; Fagnani D; Locatelli MC; Bertolini A; Valmadre G; Pavese I; Calcagno A; Sarobba MG; Marabese M
Sci Rep; 2015 Nov; 5():16331. PubMed ID: 26573509
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
11. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
[TBL] [Abstract][Full Text] [Related]
12. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H
Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer.
Xu J; Tian S; Yin Z; Wu S; Liu L; Qian Y; Pei D; Gao W; Xu J; Yin Y; Liu P; Shu Y
Lung Cancer; 2014 Sep; 85(3):442-8. PubMed ID: 24997136
[TBL] [Abstract][Full Text] [Related]
14. Variant SNPs at the microRNA complementary site in the B7‑H1 3'‑untranslated region increase the risk of non‑small cell lung cancer.
Du W; Zhu J; Chen Y; Zeng Y; Shen D; Zhang N; Ning W; Liu Z; Huang JA
Mol Med Rep; 2017 Sep; 16(3):2682-2690. PubMed ID: 28677815
[TBL] [Abstract][Full Text] [Related]
15. Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy.
Yang Y; Gao W; Ding X; Xu W; Liu D; Su B; Sun Y
Oncotarget; 2017 Mar; 8(10):16313-16324. PubMed ID: 27462918
[TBL] [Abstract][Full Text] [Related]
16. Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.
Huang X; Yang Y; Guo Y; Cao ZL; Cui ZW; Hu TC; Gao LB
Genet Mol Res; 2015 Dec; 14(4):16913-20. PubMed ID: 26681038
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.
Farahani MS; Shahbazi S; Moghaddam SA; Mahdian R
Reprod Sci; 2015 Jun; 22(6):679-84. PubMed ID: 25361550
[TBL] [Abstract][Full Text] [Related]
18. A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.
Li ZH; Pan XM; Han BW; Guo XM; Zhang Z; Jia J; Gao LB
Tumour Biol; 2013 Oct; 34(5):3159-63. PubMed ID: 23729275
[TBL] [Abstract][Full Text] [Related]
19. No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.
Luong HT; Nyholt DR; Painter JN; Chapman B; Kennedy S; Treloar SA; Zondervan KT; Montgomery GW
Hum Reprod; 2012 Dec; 27(12):3616-21. PubMed ID: 23010532
[TBL] [Abstract][Full Text] [Related]
20. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Langevin SM; Christensen BC
Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]